第2b期随机试验OX40抑制剂telazorlimab用于中度至重度的亚托皮性皮炎
Barbara Rewerska1, Lawrence D Sher2, Sady Alpizar3
1Diamond Clinic, Krakow, Poland.
The journal of allergy and clinical immunology. Global
|January 8, 2024
概括
抗OX40抗体Telazorlimab在2b期研究中显著改善了亚托皮炎. 这种治疗耐受性很好,在中度至重度病例中显示出有希望的结果.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 泰拉佐利马布是一种人性化的抗OX40单克隆抗体.
- 它正在研究用于治疗T细胞介导疾病.
研究的目的:
- 研究特拉佐利马布在阿托皮性皮肤炎患者的疗效,安全性,药理动力学和免疫性.
- 这是一项随机的,安慰剂控制的2b期剂量范围发现研究.
主要方法:
- 患有中度至重度亚托邦性皮炎的成年人接受了皮下telazorlimab或安慰剂16周.
- 剂量方案包括每2周或每4周服用300毫克,每4周服用75毫克 (第一部分),每2周服用600毫克 (第二部分).
- 主要终点是第16周湿疹区域和严重性指数 (EASI) 与基线的百分比变化.
主要成果:
- 与安慰剂相比,在16周内观察到特拉佐利马布300毫克每2周 (第1部分) 和600毫克每2周 (第2部分) 的EASI显著改善.
- 最小方位的平均EASI变化与基线相比为-54.4%vs-34.2% (第一部分) 和-59.0%vs-41.8% (第二部分).
- 泰拉佐利马布耐受性良好,治疗组和安慰剂组之间具有相似的不良事件概况.
结论:
- 皮下注射telazorlimab,特别是每两周 300 毫克或每两周 600 毫克的加重剂量后,在中度至重度的亚托皮性皮炎中显示出显著和渐进的临床改善.
- 该抗体在研究群体中耐受性良好.
更多相关视频
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
10.7K
09:32Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
7.2K
相关概念视频
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...